Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia

Dawn I Velligan, Ronald Brenner, Franco Sicuro, David Walling, Robert Riesenberg, Adonis Sfera, Charles Merideth, Dennis Sweitzer, Judith Jaeger

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

AZD3480 is a selective agonist of α4β2 central neuronal nicotinic receptors (NNRs). This study investigated its effects on cognition, relative to placebo, in 440 patients with stable schizophrenia who were taking a single atypical antipsychotic medication and who were active cigarette smokers. Mean age was 41 (range 19 to 55) years and the majority of patients (88%) had a diagnosis of paranoid schizophrenia. Patients were randomized to one of 3 doses of AZD3480: 5. mg, 20. mg, and 35/100. mg (depending on CYP2D6 metabolic status), or to placebo. Treatment was given once daily for 12. weeks. The primary outcome measure was change in cognitive function from baseline to Week 12, as measured by IntegNeuro computerized test battery of cognitive function scores. Secondary outcome measures included assessment of functional capacity (University of California at San Diego Performance Based Skills Assessment [UPSA2]) and adaptive function (Social Functioning Scale [SFS]). AZD3480 failed to improve cognition relative to placebo in this population of patients or in subpopulations defined by disposition, metabolic status, antipsychotic treatment, age, age of illness onset, and sex. Likewise, no improvement relative to placebo was observed in either the SFS measure of adaptive functioning or the UPSA2 measure of functional capacity. AZD3480 was generally well tolerated in the population studied.

Original languageEnglish (US)
Pages (from-to)59-64
Number of pages6
JournalSchizophrenia Research
Volume134
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Cognition
Schizophrenia
Placebos
Antipsychotic Agents
Outcome Assessment (Health Care)
Paranoid Schizophrenia
Cytochrome P-450 CYP2D6
Nicotinic Receptors
Age of Onset
Tobacco Products
Population
ispronicline
Therapeutics

Keywords

  • AZD3480
  • Cognitive dysfunction
  • Neuronal nicotinic acetylcholine receptor
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Velligan, D. I., Brenner, R., Sicuro, F., Walling, D., Riesenberg, R., Sfera, A., ... Jaeger, J. (2012). Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophrenia Research, 134(1), 59-64. https://doi.org/10.1016/j.schres.2011.10.004

Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. / Velligan, Dawn I; Brenner, Ronald; Sicuro, Franco; Walling, David; Riesenberg, Robert; Sfera, Adonis; Merideth, Charles; Sweitzer, Dennis; Jaeger, Judith.

In: Schizophrenia Research, Vol. 134, No. 1, 01.2012, p. 59-64.

Research output: Contribution to journalArticle

Velligan, DI, Brenner, R, Sicuro, F, Walling, D, Riesenberg, R, Sfera, A, Merideth, C, Sweitzer, D & Jaeger, J 2012, 'Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia', Schizophrenia Research, vol. 134, no. 1, pp. 59-64. https://doi.org/10.1016/j.schres.2011.10.004
Velligan, Dawn I ; Brenner, Ronald ; Sicuro, Franco ; Walling, David ; Riesenberg, Robert ; Sfera, Adonis ; Merideth, Charles ; Sweitzer, Dennis ; Jaeger, Judith. / Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. In: Schizophrenia Research. 2012 ; Vol. 134, No. 1. pp. 59-64.
@article{29a938c7846e41a39c2f202f071125ed,
title = "Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia",
abstract = "AZD3480 is a selective agonist of α4β2 central neuronal nicotinic receptors (NNRs). This study investigated its effects on cognition, relative to placebo, in 440 patients with stable schizophrenia who were taking a single atypical antipsychotic medication and who were active cigarette smokers. Mean age was 41 (range 19 to 55) years and the majority of patients (88{\%}) had a diagnosis of paranoid schizophrenia. Patients were randomized to one of 3 doses of AZD3480: 5. mg, 20. mg, and 35/100. mg (depending on CYP2D6 metabolic status), or to placebo. Treatment was given once daily for 12. weeks. The primary outcome measure was change in cognitive function from baseline to Week 12, as measured by IntegNeuro computerized test battery of cognitive function scores. Secondary outcome measures included assessment of functional capacity (University of California at San Diego Performance Based Skills Assessment [UPSA2]) and adaptive function (Social Functioning Scale [SFS]). AZD3480 failed to improve cognition relative to placebo in this population of patients or in subpopulations defined by disposition, metabolic status, antipsychotic treatment, age, age of illness onset, and sex. Likewise, no improvement relative to placebo was observed in either the SFS measure of adaptive functioning or the UPSA2 measure of functional capacity. AZD3480 was generally well tolerated in the population studied.",
keywords = "AZD3480, Cognitive dysfunction, Neuronal nicotinic acetylcholine receptor, Schizophrenia",
author = "Velligan, {Dawn I} and Ronald Brenner and Franco Sicuro and David Walling and Robert Riesenberg and Adonis Sfera and Charles Merideth and Dennis Sweitzer and Judith Jaeger",
year = "2012",
month = "1",
doi = "10.1016/j.schres.2011.10.004",
language = "English (US)",
volume = "134",
pages = "59--64",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia

AU - Velligan, Dawn I

AU - Brenner, Ronald

AU - Sicuro, Franco

AU - Walling, David

AU - Riesenberg, Robert

AU - Sfera, Adonis

AU - Merideth, Charles

AU - Sweitzer, Dennis

AU - Jaeger, Judith

PY - 2012/1

Y1 - 2012/1

N2 - AZD3480 is a selective agonist of α4β2 central neuronal nicotinic receptors (NNRs). This study investigated its effects on cognition, relative to placebo, in 440 patients with stable schizophrenia who were taking a single atypical antipsychotic medication and who were active cigarette smokers. Mean age was 41 (range 19 to 55) years and the majority of patients (88%) had a diagnosis of paranoid schizophrenia. Patients were randomized to one of 3 doses of AZD3480: 5. mg, 20. mg, and 35/100. mg (depending on CYP2D6 metabolic status), or to placebo. Treatment was given once daily for 12. weeks. The primary outcome measure was change in cognitive function from baseline to Week 12, as measured by IntegNeuro computerized test battery of cognitive function scores. Secondary outcome measures included assessment of functional capacity (University of California at San Diego Performance Based Skills Assessment [UPSA2]) and adaptive function (Social Functioning Scale [SFS]). AZD3480 failed to improve cognition relative to placebo in this population of patients or in subpopulations defined by disposition, metabolic status, antipsychotic treatment, age, age of illness onset, and sex. Likewise, no improvement relative to placebo was observed in either the SFS measure of adaptive functioning or the UPSA2 measure of functional capacity. AZD3480 was generally well tolerated in the population studied.

AB - AZD3480 is a selective agonist of α4β2 central neuronal nicotinic receptors (NNRs). This study investigated its effects on cognition, relative to placebo, in 440 patients with stable schizophrenia who were taking a single atypical antipsychotic medication and who were active cigarette smokers. Mean age was 41 (range 19 to 55) years and the majority of patients (88%) had a diagnosis of paranoid schizophrenia. Patients were randomized to one of 3 doses of AZD3480: 5. mg, 20. mg, and 35/100. mg (depending on CYP2D6 metabolic status), or to placebo. Treatment was given once daily for 12. weeks. The primary outcome measure was change in cognitive function from baseline to Week 12, as measured by IntegNeuro computerized test battery of cognitive function scores. Secondary outcome measures included assessment of functional capacity (University of California at San Diego Performance Based Skills Assessment [UPSA2]) and adaptive function (Social Functioning Scale [SFS]). AZD3480 failed to improve cognition relative to placebo in this population of patients or in subpopulations defined by disposition, metabolic status, antipsychotic treatment, age, age of illness onset, and sex. Likewise, no improvement relative to placebo was observed in either the SFS measure of adaptive functioning or the UPSA2 measure of functional capacity. AZD3480 was generally well tolerated in the population studied.

KW - AZD3480

KW - Cognitive dysfunction

KW - Neuronal nicotinic acetylcholine receptor

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84155165109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155165109&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2011.10.004

DO - 10.1016/j.schres.2011.10.004

M3 - Article

C2 - 22088556

AN - SCOPUS:84155165109

VL - 134

SP - 59

EP - 64

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -